Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis.
about
Genetic polymorphisms of CYP1A1 and risk of leukemia: a meta-analysisEuropean LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.Treatment recommendations for chronic myeloid leukemiaGlutathione S-transferase gene polymorphisms and susceptibility to chronic myeloid leukemia.Glutathione S-transferase gene polymorphisms and susceptibility to acute myeloid leukemia: meta-analyses.Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.A review of the European LeukemiaNet recommendations for the management of CML.First line treatment with newer tyrosine kinase inhibitors in chronic myeloid leukemia associated with deep and durable molecular response - systematic review and meta-analysis.Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?Involvement of primary mesenchymal precursors and hematopoietic bone marrow cells from chronic myeloid leukemia patients by BCR-ABL1 fusion gene.
P2860
Q36170488-52FB42E1-B1AB-4539-87ED-EF22BDDBDEADQ37026032-E5DE1055-6107-40E5-92A4-67CB70602F98Q38181112-A66FC51F-B60A-4A2D-BDD8-F3E21C81EC1DQ38198579-B853864D-41A3-4D49-B4DF-DA5303CD2C30Q38241982-854E14A1-F451-408F-BA13-FAA81799499CQ38261599-B2CA36AA-0017-40AC-8C1E-2E2B0D91EBB8Q38392676-061F0F15-5883-4646-A852-76053AA6B537Q38936993-A262C8D2-2168-41AC-9EDA-09B314AC2A6BQ39116591-5A845D23-AF07-4766-BD77-5AEC8358F692Q39924810-9578C414-3B49-40CD-B197-34935336CF1DQ40821920-ECD05902-898E-4325-A4EE-46EAFED3E10CQ49375952-7383B1CA-6A64-4925-B5C3-6FED37FBFD1EQ50472681-85758409-2497-43E7-B852-657798F801F5
P2860
Has the time for first-line treatment with second generation tyrosine kinase inhibitors in patients with chronic myelogenous leukemia already come? Systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Has the time for first-line tr ...... atic review and meta-analysis.
@en
type
label
Has the time for first-line tr ...... atic review and meta-analysis.
@en
prefLabel
Has the time for first-line tr ...... atic review and meta-analysis.
@en
P2093
P2860
P1433
P1476
Has the time for first-line tr ...... atic review and meta-analysis.
@en
P2093
Adi Shacham-Abulafia
Anat Gafter-Gvili
Avi Leader
Isaac Ben-Bassat
Liat Vidal
Ofer Shpilberg
Pia Raanani
Ronit Gurion
P2860
P304
P356
10.3324/HAEMATOL.2012.063172
P50
P577
2012-08-08T00:00:00Z